Skip to content

Sections
- Health
- Pharma
- Biotech
- Hospitals
- Politics
- In the Lab
- First Opinion
- Gut Check
- The Watchdogs
Topics
- Cancer
- Concussions
- CRISPR
- Drug Pricing
- End of Life
- Health Disparities
- Immigration
- Opioids
- Trump
- Women’s Health
- Zika
Multimedia
Popular
STAT Plus

Job Board
About

Newsletters
My Account
- Settings
- Log Out

Newsletters
My Account
- Settings
- Log Out

Clinical Trials

Biotech

Bluebird Bio’s gene therapy for blood disorders yields some impressive results ― but also raises questions

By Adam Feuerstein

First Opinion

How do we solve the crisis in cancer communication?

By Lynn O'Connor Vos

advertisement

Where are they now

Experimental scaffold hasn’t reversed her paralysis, but she’s embraced life ‘with wheels as legs’

By Rebecca Robbins

advertisement

Gut Check

Do cancer clinical trials exaggerate the real-world benefits of drugs?

By Sharon Begley

Pharmalot

How much longer will Gilead wait before buying its way out of the doldrums?

By Ed Silverman

Health

‘Colontown’ gives cancer patients an edge in finding new treatments

By David Steen Martin

First Opinion

Right-to-try laws could curtail the development of innovative new therapies

By Alison Bateman-House

advertisement

Business

Novel system to get dying patients an experimental cancer drug raises hopes — and thorny questions

By Karen Weintraub

advertisement

Pharmalot

What clinical trial results? Now you can see who isn’t sharing their findings

By Ed Silverman

First Opinion

In defense of data sharing, but done in the right way

By Jeffrey M. Drazen and Isaac S. Kohane

In the Lab

Major trial casts doubt on leading device to heal bone fractures

By Charles Piller

First Opinion

Assess institutional review boards by their quality of decisions, not ownership

By Stephen Rosenfeld and Jim Gearhart

Pharmalot

Pharmalot, Pharmalittle: Drug makers are making huge bets on some cancer meds

By Ed Silverman

In the Lab

Amid crisis, Ebola drug narrowly missed threshold to prove effectiveness

By Andrew Joseph

In the Lab

Should researchers study bunk science? Among respected scientists, a debate ensues

By Helen Branswell

Pharmalot

Pharmalot, Pharmalittle: Alnylam stock plunges after key clinical trial is ended

By Ed Silverman

Health

For cancer patients, newest treatments force the ultimate decision, with no room for error

By Bob Tedeschi

In the Lab

Novel study of pancreatic cancer aims to give patients more treatment options

By Sharon Begley

Pharmalot

European regulators appeal rulings that prevent release of drug data

By Ed Silverman

First Opinion

Bad science misled millions with chronic fatigue syndrome. Here’s how we fought back

By Julie Rehmeyer

Health

For two brothers with Duchenne, an FDA drug approval brings joy and relief

By Jeffery DelViscio

Politics

New federal rules target woeful public reporting of clinical trial results

By Charles Piller

Exclusive

As Parkinson’s patients wait, Fox Foundation and scientist feud over drug trial

By Charles Piller

First Opinion

5 top blunders life science startups make on the road to clinical trials

By Laurie Halloran

The Watchdogs

Many clinical trials’ findings never get published. Here’s why that’s bad

By Ivan Oransky and Adam Marcus

The Watchdogs

NEJM editorial doubles down on resistance to data sharing

By Ivan Oransky and Adam Marcus

Pharmalot

Many pediatric clinical trials go unpublished or unfinished

By Ed Silverman

Biotech

Elizabeth Warren demands open access to data from patient trials of drugs

By Meghana Keshavan

Pharmalot

Pharmalot, Pharmalittle: The debate over data sharing heats up again

By Ed Silverman

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.

Sign up for our morning rounds newsletter

Reporting from the frontiers of health and medicine

About
Contact Us
The STAT Team
Work at STAT
Job Board
Advertise

Privacy
Comment Policy
Terms

© 2017 STAT